KRAS Inhibitors: Positive Phase 2 Results in Pancreatic and Gastrointestinal Cancers

Recently, Mirati Therapeutics announced that its KRAS G12C inhibitor adagasib has achieved positive results in the KRYSTAL-1 Phase II clinical trial

In a cohort of previously treated patients with pancreatic duct adenocarcinoma and other gastrointestinal (GI) cancers with KRAS G12C mutation, adagasib demonstrated significant clinical activity and broad disease control

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor with durable targeted inhibition

Last June, the U.

The test results show:

As of September 10, 2021, the objective response rate (ORR) for evaluable patients (n=27) was 41% and the disease control rate (DCR) was 100%

Among evaluable pancreatic cancer patients (n=10), response rate (RR) was 50%, including 1 unproven partial response (PR); median duration of response (mor) was 7.

The RR was 35% for patients with other gastrointestinal tumors (n=17), 2 of whom had undiagnosed gastrointestinal tumors; the mor for these patients was 7.

Median progression-free survival (mPFS) was 6.

Agraxib is well tolerated and has a manageable safety profile